Summit Therapeutics at Goldman Sachs Healthcare Conference: Strategic Advances in Cancer Treatment

On Monday, June 9, 2025, Summit Therapeutics PLC (NASDAQ:SMMT) presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025, discussing strategic advances in cancer treatment. The conference highlighted the promising progress of Summit’s lead molecule, ivenosumab (Ivo), while also addressing challenges in clinical trials and financial strategies.

Key Takeaways

• Summit’s lead molecule, ivenosumab (Ivo), shows promising trends in overall survival in clinical trials.
• The company holds over $360 million in cash reserves, supporting ongoing clinical development.
• Summit is transitioning to in-house manufacturing capabilities in various regions.
• The company is actively seeking partnerships to expand Ivo’s potential and focus on combination strategies.
• Despite not reaching statistical significance in some trials, Summit remains confident in Ivo’s potential.

Financial Results

• Cash Position:

- Summit ended Q1 with over $360 million in cash.

- The company raised over $400 million in the previous year.

• Q1 Run Rate:

- The Q1 run rate was approximately $50 million, with expectations for an increase.

• Future Funding:

- Summit acknowledges the need for additional capital for ongoing development.

- Plans to raise funds strategically to maximize stakeholder wealth.

Operational Updates

• Clinical Development Plan:

- Summit plans to expand its clinical development, with over 22 trials ongoing or planned.

- 11 of these are Phase III trials in collaboration with Akeso, involving over 3,000 patients.

• Manufacturing Strategy:

- Currently reliant on Akeso for production, with a shift towards in-house capabilities in the US, Europe, Japan, Africa, and the Middle East.

Future Outlook

• Data Release Timelines:

- HARMONY data will be presented at upcoming medical meetings in the fall.

- Further details on the expansion of the clinical development plan will be provided.

• Partnership Strategy:

- Summit is actively seeking partnerships to enhance Ivo’s potential through combination strategies.

• Commercialization Strategy:

- Leveraging Ivo’s safety profile for combinations with other therapies and exploring collaborations with companies like Pfizer.

Q&A Highlights

• HARMONY Study OS:

- The hazard ratio of 0.777 did not reach statistical significance (p-value of 0.057).

- Summit considers the study scientifically positive and plans to present findings to the FDA.

• Enrollment Strategy:

- Future trials aim for more balanced regional enrollment, acknowledging the prevalence of Asian patients in EGFR mutant trials.

• Competition:

- Summit welcomes competition as validation of their approach, emphasizing the quality of Ivo and strong partnerships, such as with MD Anderson.

Readers are encouraged to refer to the full transcript for a detailed overview of Summit Therapeutics’ presentation and strategic insights.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference 2025:

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Great. Good afternoon, everyone. Thank you so much for joining us. I’m Salveen Richter, Biotechnology Analyst at Goldman Sachs. And we’re really pleased to be joined by the Summit team who’s rather patriotic today.

So to start here next to me, have Mickey Zengene, who’s Co CEO Bob Duggan, Co CEO Manmeet, Sony, COO and CFO and Dave Genzar’s Chief Business Officer. So with that, to start here, could you provide an overview of your lead molecule, Ivo, and where your programs stand, your strategy for your company and the key events we should focus on in the half and beyond?

Bob Duggan, Co-CEO, Summit: Dave? I was going to give it to McGee. McGee is the cover girl of the upcoming Forbes Magazine, and you’ll hear plenty from her today. But Dave, go ahead.

Dave Genzar, Chief Business Officer, Summit: Sure. Thanks for the question, Salveen. So I think as we take a look back over 2025 thus far, so we had announced at the beginning of the year that there would be three clinical catalyst events and one operational catalyst event. And so we began the year stating that there would be we would focus on the ability to translate PFS into OS in the HARMONY-two study monotherapy, ibenzumab and pembrolizumab in the PD L1 positive non small cell lung cancer frontline setting. We would focus on the success that took place in HARMONY two in the monotherapy setting and seeing that translate that benefit translate into the chemo combination setting.

So as we look at non small cell lung cancer and solid tumors as a whole, the overwhelming standard of care in the frontline setting is often immunotherapy plus chemotherapy. And then we would look to show that the success in single region, albeit randomized Phase III studies in China, would be comparable to the results in a multiregional setting a la HARMONY A to the HARMONY trial in line EGFR mutant non small cell lung cancer. So all three of those data points read out earlier this year. And so we saw a strong positive trend in overall survival, and a health authority requested look at overall survival in HARMONY two. That showed a hazard ratio of 0.777 at a nominal alpha spend, given that that was requested by the health authority as opposed to a preplanned analysis.

And so that showed a strong favorable trend. And so we see, oftentimes, we look at clinically meaningful as being about 0.8. And so the look at thirty nine percent data maturity showed positive and encouraging trends from there. And also important to note that this trial at three ninety eight patients was intended to evaluate statistical significance of overall survival as this was a primary endpoint of PFS, and that indication for ivenizumab has since been approved in China. The aspect, chemo combination in HARMONY six, looked at frontline squamous non small cell lung cancer, and that took a look at ivanesumab plus double chemotherapy against PD-one plus double chemotherapy.

In that trial, our partners at Akeso announced was strongly positive on the look at PFS. That was, again, a PFS primary endpoint. And that data will read out in full at a major medical conference later this year. But that data, it’s a interim look, so obviously it’s a relatively high bar from a statistical plan perspective. And therefore, it continues the favorable news and data with respect to ibonesumab now in a chemo combination, which is important as we look at the opportunity in solid tumors as a whole and in particular in non small cell lung cancer.

And then finally, with respect to the data comparability from single region China to a multi regional setting, the HARMONY trial read out just before ASCO, and that showed a statistically significant and clinically meaningful progression free survival and a strong trend in overall survival, the two primary endpoints, which was consistent with what we saw in the HARMONY A trial from the single region study in China, further validating that the randomized Phase III that we see in China continue to validate the opportunity as a whole for advenesumab in a global setting. The final operational catalyst that we discussed earlier was the expansion of our clinical development plan later this year, and we continue to effectively reaffirm our intentions from that perspective. So hopefully, that gives decent color in terms of overall summary to date on where we are and what’s taking place over the last few months.

McGee (Mickey) Zengene, Co-CEO, Summit: And I just want to add as well, for sure, we have our partner, Akeso, as you know, in multiple different meetings, we announced as well that we have over 22, 23 different trials going on, all completed, all going to start. But 11 of that is a Phase III that China and us, we are combining. We are doing that. Over 3,000 patients is enrolled. So we have a very good safety profile, efficacy profile in many different therapeutic area as well as from commercialization point of view, we already in China, we got two FDA two Chinese approval, which is significant from the progress that we are going to have here in America and the fact that right now they are selling the drug and it’s more than twenty twenty five thousand patients already enrolled with this product.

And that is already talked a lot from, as I said, safety and efficacy point of view.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Maybe we can start here with the HARMONY study, just given we saw the data recently ahead of ASCO. Help us understand next steps from here for you in terms of providing data to us, but also in terms of what you might want to provide to the FDA down the road. And then also, just the meaningfulness of this indication in the context of the total opportunity that you’re pursuing?

Dave Genzar, Chief Business Officer, Summit: Sure. So for the last question I think from an opportunity perspective, this was an important setting from a speed perspective as we look to enter the market for ivenosumab. From a total addressable market perspective, think of it as probably 1% to 2% of the total addressable market within the possibility for ibotsumab. When we look at the data itself, so we were statistically significant and clinically meaningful in progression free survival and a strong positive trend without hitting statistical significance in overall survival. When we look at this setting, so you would ask Salveen with respect to filing and whatnot.

We noted in our release that we intend to file a BLA, but we want to make sure that we think through strategically the right next steps with respect to how to do that. So when we entered into the agreement with Akeso, this was a specific opportunity, as I mentioned a minute ago, to move quickly in this setting. This is a setting where PD-one therapies have looked to become a part of, but both pembro and nivo had unsuccessful trials in this setting in both PFS and OS. So this was a differentiation point for ipinacumab against the existing PD-1s. So we were very thankful in working with the agency from the beginning in 2023, and we appreciate the agency working with us in terms of moving forward here in this study immediately.

And so we, at the agency’s request, included overall survival as a primary endpoint along with progression free survival. And so when the study read out, we were, again, statistically significant, meaningful in progression free survival, but the agency asked for statistical significance as well with overall survival. When we look at the landscape for this particular patient setting, We see one approved regimen in this space that also showed a PFS statistical significance and an OS trend without hitting statistical significance. So as we look at the overall package, we just want to work through strategically the right way to bring this forward as we work with the agency with respect to next steps. At ASCO, as Salveen mentioned, we’re it was just ahead of the conference where we disclosed this data.

We had a couple 100 interactions with either KOLs or other physicians who were attending the conference, and was overwhelmingly positive in terms of the opportunity evenesibab plus double chemotherapy, the HARMONY regimen, if you will, what options that could provide in this particular setting. So we think it’s a very good overall data package, and we’re working with internally to determine what are the right appropriate next steps, if you will, strategically. We had mentioned in our release the Friday before last that the patients from the Western countries, the median follow-up time was actually less than the median overall survival in this setting. So we think there’s value in continuing to follow all patients, but in particularly the patients from the Western countries in terms of adding to the overall package here.

McGee (Mickey) Zengene, Co-CEO, Summit: Bob, do you want to add something or? No. No? Okay.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Maybe a twofold follow-up to that. So one is, do you have an understanding of what’s required from your clinical trial program in the context of ex China data sets versus China data sets and how you think about that in the context of your overall program on the FORWARD? And then the bar for approvability at the FDA with these dual endpoints and the optimization that you have done to ensure you can hit on overall survival as well as PFS?

Dave Genzar, Chief Business Officer, Summit: Sure. And so with respect to the question, yes, each of our trials, we work with the agency in advance in terms of proportion of enrollment amongst other factors, design of the trial, etcetera. And so going forward, you can expect much more of in a for example, if there’s three regions within the study, about onethree in one region, onethree in another region, and onethree in the final region, more even split. As we mentioned with eGFR, it’s a higher prevalence in patients of Asian descent. And so typically, you see eGFR mutant trials have a higher proportion of enrollment from Asia.

But going forward, in other indications, you would expect much more of an even enrollment across, and that’s effectively what we have planned for our two enrolling trials at this point. With respect to the approvability, again, as we continue to have conversations with the agency, these details are worked out. I would say we started HARMONY three with an overall survival primary endpoint. And part of the reason for adding a dual primary endpoint when we added non squamous on top of the squamous population was in response to the data that we saw in HARMONY two that had such a profound PFS benefit that we wanted to at least ensure the ability to have a conversation with the agency should agency should PFS readout with such a significant difference in the HARMONY-three. However, we started with OS as the sole primary endpoint in that trial.

And I think it’s very clear that within the frontline non small cell lung cancer setting, that will become extremely important in terms of showing an overall survival benefit over PD-one plus chemotherapy in terms of realizing the potential of the market. And as we I mentioned in the opening, HARMONY two had early look, but it showed a very positive or favorable trend in terms of its look. So that continued to provide positive data that was encouraging. And then also, we have obviously a significant amount. McKee mentioned the number of trials, well over 20 trials that has been enrolled or enrolling.

Those include a number of Phase II trials as well in this particular settings where we can see the follow-up that’s much longer now than what you see in the Phase III, and we’re very encouraged by what we see there. So you see the powering of our clinical trials in that we run on a multi regional basis, and those are intended to and are powered for statistical significance and overall survival.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Just one last question on HARMONY. What do you think played out here with regard to the trial that OS was not statistically significant? Was it powering? Or was it tumor type or other factors? Maybe help us understand what you think played out.

McGee (Mickey) Zengene, Co-CEO, Summit: I can start and then after that. I mean this study is was very interesting study. It was already enrolled in China. And when we did the deal with EKESO, which was around February 2023, we started right away, we were in discussion with the FDA. And for sure, the discussion was to add additional patients into the Chinese patient populations, which is onethree, thirty eight percent, forty percent of these trials is ex U.

S. Patients. And we enrolled we started enrollment as soon as possible. For sure, at this moment of time, as well, it was a time that we take a little bit to everybody questioning what is the bispecific, everybody questioning what is the China data, everybody it just was so much question. So the three months took us a little bit time, and especially for the company like us that we didn’t have Phase one, Phase two, we started right away on the Phase three to bring awareness to the physicians, to the patients, took a little bit longer time to take off on these specific trials.

And for sure, last ASCO and September when we announced our data, the enrollment went really, really fast in this regard. And I know sometimes the people say the study was not statistically significant. But if you really, really look at it, the p value, the I mean, the hazard ratio was 0.79, which is already unbelievable for this category of patient population. There is no other drug at this moment of time got the OS, one. if you really look at the safety profile of these for these patient populations compared to existing drug, I mean, you cannot compare, which is a better safety profile.

The efficacy was good. The only thing I can say, you say significant, and that is the difficulty when you look at the OS p value of 0.057 instead of 0.05 is really you’re playing with the penny numbers. It’s not you cannot say that the drug is not working. You cannot say the drug is not good for this patient population. So if you take a little bit another look on it, at the end of the day, as a physician, as a human being, as a patient, you cannot just go and say because you didn’t hit 0.057, you cannot prescribe this drug into the patient.

And some moment of time will come, either it will be on the NCCN guidelines, we are trying to go back to FDA to present our case. And there’s a lot of other things. At the end of the day, we have to do everything possible to bring this drug in the hand of patients. That is bottom line. So therefore, yes, perhaps this number shows that say, oh, we didn’t hit it.

But in the reality, I believe the study was quite was very positive scientific point of view about it.

Bob Duggan, Co-CEO, Summit: Yes. I’d like to give Doctor. Pauzer a lot of credit. He could have easily agreed with the early take from the FDA was too much China data and we just don’t do that now. And he stepped in and took a look at it and he is familiar with McKean and myself from Pharmacycloexistase and put a call and just said, I have a question.

What is it? He said, why did you do this? He said, there’s a major unmet need around the world. We think this molecule has some real life to it. And honestly, given what we’ve seen, we just felt we had an obligation to try to work this out.

So he paused. He said, well, it makes sense. He said, I’ll let you do it, but the challenge is going to be OS. Now there had not that was like impossible. But we took it because what it could possibly show even if we didn’t hit the OS at 0.05 is that the data is translatable.

The progression free survival was spectacular. OS is not even a question in eGFR, TKI, post TKI. So we thought all those would be wins. And in fact, they were. That’s why you can look at the trial and say, it did succeed.

But I give him a lot of credit for, one, helping the two countries come together under something very substantial. We are exporting China technology. China’s exporting the technology, we’re importing it. We exported money. It’s exactly what the country wants.

They want the money in and the tech out around the world. So this is just one small step really for mankind and humankind. We’re not in the war business, we’re not in the IT business, we’re not in the AI business, although we use AI a lot. It just shows these two people, these two peoples can’t get along. And we do and we did and we’ll continue.

Our top partners from McKesson are, like many Chinese, educated in America. They’re culturally Chinese. They speak both languages. They have American passports. And we see every reason why we should get along, not why we shouldn’t.

And we did this before Jamie Dimon and Henry Kissinger, rest his soul, went over to China to say, these two countries really ought to be getting along. So if you’re going to get something going, this is the easiest patch in which to launch this. So we’re happy with our partner. We’re really there’s no question about it. Ivo is a working drug.

And we’re pleased to find post the relationship that outside of NSCLC, there may be a bigger opportunity than Incyte. So that’s what I can say about this.

McGee (Mickey) Zengene, Co-CEO, Summit: And the last thing for us was really important because instead to do a Phase one, Phase two, you go right away in the Phase three and shows the Western patients versus Eastern, I mean China versus ex China U. S. And this consistency of the data. That was the win, the biggest win that everybody wanted to see what’s going to happen, what is the China data. So if you look at it in a different angle, at the end was a lot of win win position in this situation to do this study no matter the challenges.

But the rest of the study is different because, as you know, the global study mostly is onethree China, twothree ex China is always now is onethree Europe, onethree U. S. So it’s a different dynamic. This one was very interesting, exceptional trials that we wanted to finish it.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: I want to touch on one of the biggest opportunities you have in cancer in your frontline non small cell lung cancer opportunity here with HARMONY-three. So you’ve talked about how it’s enrolling faster than expected. I don’t believe you’re going to give us timelines yet, but we’ll wait for them. But in the interim, maybe walk us through the Kesso trial from HARMONY six that looked at their combination of Ivo with chemo in frontline squamous non small cell lung and just frame that result and the read through to your study and also the differences that are playing out with your program versus the ACASAR trial?

Dave Genzar, Chief Business Officer, Summit: Yes. I think you framed that well, Salveen, in terms of frontline squamous non small cell lung cancer, Ivo plus chemo versus tislelizumab, which is the PD-one from Beijing, the PD-one inhibitor plus chemotherapy. And Tislel plus chemotherapy, for example, is approved in Europe as a standard of care for frontline non small cell lung cancer. And so that study PFS primary endpoint squamous, but it’s PD L1 all comers, right, so negative low and high. And so compare that against our HARMONY three study, which we’re enrolling on a multi regional basis, PFS, OS, dual primary endpoints, and we talked about OS a minute ago.

The PD-one is pembrolizumab in that setting, and it’s squamous and non squamous, and of course, multi regional versus single region, right? And so I think as we see now, as I talked about in the beginning, we saw the PFS to OS in HARMONY two. We saw the top line data readout from HARMONY six in the squamous chemo combination setting. And so now as we look at HARMONY three, the read through also is further backed up by the consistency of the results from HARMONY A and HARMONY as well, right? So more multi regional studies will continue as we go into HARMONY three and seven.

But it’s important that there’s now been three successful Phase 3s randomized Phase three trials against standard globally reputable standards of care, if you will, now run by our partners at Akeso. And so as we look at the data that there will be more data that’s disclosed on that in the fall at a major medical conference. But in the interim, it gives us it further validates our confidence within the frontline setting, and it provides additional data points as we look at all of the major milestones that need to be accomplished in terms of the opportunity for ibinesumab to eventually change standards of care on a multi regional basis.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Can you touch on the strategy here for execution across this very broad space with this drug and how you intend to do that and move into various tumor types in a very quick fashion, recognizing that now you have all these followers with other large biopharmas that are doing partnerships with drugs in the same class.

McGee (Mickey) Zengene, Co-CEO, Summit: Do you want to take it?

Bob Duggan, Co-CEO, Summit: Yes. The Ivo is the best drug from everything we’ve seen and understand. The source of Ivo is Akeso, and they started in 2013 and brought the product out because Mickey said there’s over 20,000 patients dosed majorly successfully. They’re dosing 200 patients a clip a day. Our trials are enrolling.

They’re enrolling fast. So we’re pleased with all of that. It doesn’t surprise us that there are a lot of followers who could be in this business and not see someone with a loss of entity value and approval going in 2028 off label and not one after. It’s a $30,000,000,000 business plus. There’s easily another 20,000,000,000 off target from NSCLC.

So when we did IMBRUVICA, we were the only ones until we showed that it worked. Within six months, there were 100 IMBRUVICA patents. So it’s not difficult to come up with a molecule. No one has matched the molecule. Those that have graded it have looked at it and said, we are the best.

So if you’re in a horse race, you want the fastest horse. If you’re the fastest horse, you still need the best jockey. And we think we’re good jockeys, but we think partnering is going to be the way to go to really get it across the finish line. So we’re going to actively engage in that activity. We wanted to show what we could do, what we should do and let the field settle down a little bit, But you’ll we’re going to be very active in that area.

So with the right partner, with the right drug, with the leadership from Akeso in terms of pushing outside the NSCLC arena, we think we’re pretty pleased with where we stand here. And we do appreciate competition. It’s basically a validation that what we have is right. The great thing about this business is the FDA gives you an AMA, work it hard on it to make sure that this happens. You have a monopoly unless someone is better than you.

So it’s not going to be easy to fund the other businesses that have to go head to head with Pembro, much less ourselves, who then beat Pembro. But we need to establish that partnership and get rolling. But we’ve let no grass grow under our feet. We’ve got over 50 ISTs. We also have six of them have already launched.

We have a big partnership with MD Anderson. So there’s no one out there now, unlike the four months when we took the drug over, no one knew bispecifics or activity. No one knew that EGFR was not going be a major bleeder in this space. No one wanted to partner with China and no one really heard the name of Summit. That was a real stiff wall to climb, but that’s been climbed now.

So this is our game to win.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: And how are you thinking about it from a combinatorial strategy standpoint across the cancer space? All of the good patients with different modalities or targets?

McGee (Mickey) Zengene, Co-CEO, Summit: The good news is and I will let after that Dave answer more details. But the good news is that we have a very nice safety profile. You can combine with any drug that you want to. We do not I mean, if it’s a combination with the ADC of the world or any other combinations, We are working on that. And while we come up, we will announce it.

But you go like any other at the end of the day, you are in solid tumors. At the end of the day, you have a patient’s perspective. At the end of the day, every month count, every day count. At the end of the day, you want to give the best, safest product in the hands of patients, at the same time, the most efficient drug in the hands of patients. So we will do everything possible to figure out what is the best combinations that they give these two safety and efficacy to their patients.

But you have to try it. And on our side, we have one product that we can combine it to any other product that we want to with any partners that we want to. There’s no restriction. If we did a collaboration with Pfizer, it doesn’t allow us to do with other people on the collaboration with the agency.

Dave Genzar, Chief Business Officer, Summit: Well said.

McGee (Mickey) Zengene, Co-CEO, Summit: Thank

Salveen Richter, Biotechnology Analyst, Goldman Sachs: you. Mandeep, maybe you could touch on the balance sheet at this point and what it covers in terms of clinical development.

Manmeet Soni, COO and CFO, Summit: Sure. So as you know, we finished our Q1 with over $360,000,000 in the bank. We raised around $400 plus million last year. We know that. We need capital, right, to continue the development, but we have sufficient our run rate for Q1 was approximately $50,000,000 which will continue to increase, but we have sufficient capital to continue to execute on our current plans.

And as appropriate, Bob have always said that when appropriate, we will raise money.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: Can you also speak to the manufacturing strategy here?

Manmeet Soni, COO and CFO, Summit: Sure. On manufacturing front, as you all know, Akiso being the partner and developing Ivo, we have been relying on them for doing our clinical trials, and they have been producing. They have gone through their inspections and including FDA inspection for another product. So they have passed through that. In the meantime, we have right to develop in our territories, and our territories includes U.

S, Europe, Japan, Africa and Middle East. We have full rights to develop and manufacture Habenasnap. We initiated tech transfer last year, and we are progressing pretty well on the tech transfer. So we believe pretty soon we should have capability to produce ourselves in our own territories, which will help us.

Bob Duggan, Co-CEO, Summit: On the cash side, you all are investors and you wouldn’t be here if cash earned a super huge return annualized, it doesn’t. You need to get into equities, need to get into real estate, you need to do something alternatives to cash. As Buffett said, he’s 94 years old, the dollar lost 92% of his value during that period of time. That’s not going to change in anybody’s lifetime. So there’s plenty of cash out there.

The question is, does the owner of the cash have confidence in the business and the opportunity? And that answer is yes, the cash transfers, whether it’s a recession, inflation or rapid growing economy. So we have not only the molecule, we have the source of the molecule and a relationship with them. We have all you check all the boxes and we are really set to go. We didn’t want to compound a potential relationship in the making with raising cash.

So we don’t need $2,000,000,000 on our balance sheet because we’re talking about how we can put this company together and maximize the wealth opportunity for the stakeholders in the business in addition to the opportunity for patients and society at large. So when those chips fall, then we can further entertain the question of cash. Whether we need it or we don’t, I don’t think we will.

Salveen Richter, Biotechnology Analyst, Goldman Sachs: As a last question here, could you speak to the data sets that we’re going to see over the next six to twelve months across both your portfolio and Akeza’s portfolio? And if there’s anything that I didn’t ask about that you want to highlight, I would do so as well.

Dave Genzar, Chief Business Officer, Summit: Sure. So great set of questions, so thank

Bob Duggan, Co-CEO, Summit: you very much.

Dave Genzar, Chief Business Officer, Summit: So nothing too profound to highlight other than so data sets will see Harmony over the course of fall meetings or whatnot. We’ll also see HARMONY six. So we’ll see multi regional HARMONY, second line EGFR that we sponsored, HARMONY six frontline squamous combination with chemo sponsored by Akeso. I think we’ll also not a data set, but we’ll also give further clarity with respect to the expansion of our clinical development plan. And I think we’ll also likely start to give a little bit more for timelines with respect to Harmony three, which we started a little while ago.

So I think in terms of that, we’ll likely have additional other components, but there’s no reason to give away the full story before, and it’s always good to have something else come into play.

McGee (Mickey) Zengene, Co-CEO, Summit: But overall, we have a great product. We have a great team. We have the speed of light. I believe we show it with 185 people. We really did an outstanding job in the past two years.

We showed to the world, and I believe you saw it with every quite specific, like a mushroom is coming up, that is a kind of we showed the molecule is a significant and important molecule to have. And I at the end of the day, again, people, they are afraid on competitions. Personally, I’m not because I believe every patient deserve to the product that is working on you perhaps is not going to work on me. So at end of the day, we’ll do everybody possible to bring the best product in the hand of patients. So we are in a great shape.

That’s the only thing I can say. The entire team is working very, very hard, and we have great physicians, as Bob said. Our ICD program is moving very, very nicely in the different indications. Our partner did an outstanding job as well. Bringing Phase III in such a short period of time is important and significant.

And we are very I cannot say lucky, but I’m just saying we are pleased that they start the Phase III, and we can take it and bring the data and start our Phase III so we don’t need to go to the Phase I, Phase II process. Right now, we can catch the data from our partner, IKESO, and start right away another Phase III. For sure, our regulatory group from China and U. S. Is different.

That is why we powered our trials there have more patients because we powered for the OS and PFS. So that’s where we are.

Bob Duggan, Co-CEO, Summit: Before we end off, let me give a shout out to Salveen and her Goldman Sachs They do an unbelievable job of following this company in-depth. It’s not easy, but we’re really appreciative and the work that Goldman does for all of us to bring liquidity to markets like we participate in. So thank you so much, Sophie.

McGee (Mickey) Zengene, Co-CEO, Summit: Thank you. Thank you.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.